LH vs. MRNA: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at LH and MRNA, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | LH | MRNA |
|---|---|---|
| Company Name | Labcorp Holdings Inc. | Moderna, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Biotechnology |
| Market Capitalization | 23.11 billion USD | 10.46 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | March 29, 1990 | December 7, 2018 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of LH and MRNA by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | LH | MRNA |
|---|---|---|
| 5-Day Price Return | 2.53% | 0.75% |
| 13-Week Price Return | 11.33% | 1.89% |
| 26-Week Price Return | 13.57% | -15.76% |
| 52-Week Price Return | 22.97% | -70.11% |
| Month-to-Date Return | 6.93% | -9.03% |
| Year-to-Date Return | 21.27% | -35.33% |
| 10-Day Avg. Volume | 0.54M | 7.78M |
| 3-Month Avg. Volume | 0.75M | 9.92M |
| 3-Month Volatility | 23.10% | 54.60% |
| Beta | 0.90 | 2.05 |
Profitability
Return on Equity (TTM)
LH
9.25%
Health Care Providers & Services Industry
- Max
- 26.03%
- Q3
- 13.74%
- Median
- 8.26%
- Q1
- 4.13%
- Min
- -3.62%
LH’s Return on Equity of 9.25% is on par with the norm for the Health Care Providers & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
MRNA
-27.46%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
MRNA has a negative Return on Equity of -27.46%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
LH
5.66%
Health Care Providers & Services Industry
- Max
- 12.40%
- Q3
- 5.93%
- Median
- 1.96%
- Q1
- 0.93%
- Min
- -6.10%
LH’s Net Profit Margin of 5.66% is aligned with the median group of its peers in the Health Care Providers & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
MRNA
-94.31%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
MRNA has a negative Net Profit Margin of -94.31%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
LH
8.83%
Health Care Providers & Services Industry
- Max
- 19.05%
- Q3
- 10.21%
- Median
- 4.22%
- Q1
- 1.98%
- Min
- -4.27%
LH’s Operating Profit Margin of 8.83% is around the midpoint for the Health Care Providers & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
MRNA
-106.34%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
MRNA has a negative Operating Profit Margin of -106.34%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | LH | MRNA |
|---|---|---|
| Return on Equity (TTM) | 9.25% | -27.46% |
| Return on Assets (TTM) | 4.20% | -21.24% |
| Net Profit Margin (TTM) | 5.66% | -94.31% |
| Operating Profit Margin (TTM) | 8.83% | -106.34% |
| Gross Profit Margin (TTM) | 28.14% | 68.32% |
Financial Strength
Current Ratio (MRQ)
LH
1.50
Health Care Providers & Services Industry
- Max
- 2.01
- Q3
- 1.49
- Median
- 1.30
- Q1
- 0.94
- Min
- 0.17
LH’s Current Ratio of 1.50 is in the upper quartile for the Health Care Providers & Services industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
MRNA
3.93
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
MRNA’s Current Ratio of 3.93 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
LH
0.67
Health Care Providers & Services Industry
- Max
- 2.17
- Q3
- 1.18
- Median
- 0.74
- Q1
- 0.45
- Min
- 0.00
LH’s Debt-to-Equity Ratio of 0.67 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
MRNA
0.01
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
MRNA’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
LH
5.73
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.15
- Median
- 5.45
- Q1
- 2.04
- Min
- -4.44
LH’s Interest Coverage Ratio of 5.73 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.
MRNA
--
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
Interest Coverage Ratio data for MRNA is currently unavailable.
Financial Strength at a Glance
| Symbol | LH | MRNA |
|---|---|---|
| Current Ratio (MRQ) | 1.50 | 3.93 |
| Quick Ratio (MRQ) | 1.08 | 3.59 |
| Debt-to-Equity Ratio (MRQ) | 0.67 | 0.01 |
| Interest Coverage Ratio (TTM) | 5.73 | -- |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
LH
1.05%
Health Care Providers & Services Industry
- Max
- 5.38%
- Q3
- 2.22%
- Median
- 0.55%
- Q1
- 0.00%
- Min
- 0.00%
LH’s Dividend Yield of 1.05% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
MRNA
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
LH
31.71%
Health Care Providers & Services Industry
- Max
- 186.69%
- Q3
- 74.82%
- Median
- 26.76%
- Q1
- 0.00%
- Min
- 0.00%
LH’s Dividend Payout Ratio of 31.71% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
MRNA
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | LH | MRNA |
|---|---|---|
| Dividend Yield (TTM) | 1.05% | 0.00% |
| Dividend Payout Ratio (TTM) | 31.71% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
LH
30.27
Health Care Providers & Services Industry
- Max
- 55.89
- Q3
- 30.85
- Median
- 21.17
- Q1
- 12.63
- Min
- 0.00
LH’s P/E Ratio of 30.27 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
MRNA
--
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for MRNA is currently unavailable.
Price-to-Sales Ratio (TTM)
LH
1.71
Health Care Providers & Services Industry
- Max
- 3.10
- Q3
- 1.74
- Median
- 0.67
- Q1
- 0.24
- Min
- 0.00
LH’s P/S Ratio of 1.71 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
MRNA
3.39
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
In the lower quartile for the Biotechnology industry, MRNA’s P/S Ratio of 3.39 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
LH
2.59
Health Care Providers & Services Industry
- Max
- 7.61
- Q3
- 4.32
- Median
- 2.53
- Q1
- 1.14
- Min
- 0.77
LH’s P/B Ratio of 2.59 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
MRNA
1.14
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
MRNA’s P/B Ratio of 1.14 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | LH | MRNA |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 30.27 | -- |
| Price-to-Sales Ratio (TTM) | 1.71 | 3.39 |
| Price-to-Book Ratio (MRQ) | 2.59 | 1.14 |
| Price-to-Free Cash Flow Ratio (TTM) | 16.88 | 34.41 |